Clinical trial
Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic…
NCT00004861 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00004861 |
|---|---|
| Title | Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CI-994 Capsules Plus Gemcitabine Infusion Versus Placebo Capsules Plus Gemcitabine Infusion in the Treatment of Patients With Advanced Pancreatic Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, tacedinaline |
| Start date | Oct 1, 1999 |
| Completion | Sep 1, 2001 |
| First posted | Jun 18, 2004 |
| Last update posted | Aug 10, 2012 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: